The estimated Net Worth of Kimberly Manhard is at least 2.61 百万$ dollars as of 28 August 2024. Ms. Manhard owns over 10,000 units of Heron Therapeutics Inc stock worth over 18,100$ and over the last 10 years she sold HRTX stock worth over 86,380$. In addition, she makes 2,509,870$ as Executive Vice President - Drug Development、 Director at Heron Therapeutics Inc.
Kimberly has made over 24 trades of the Heron Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she bought 10,000 units of HRTX stock worth 139,800$ on 28 August 2024.
The largest trade she's ever made was exercising 24,000 units of Heron Therapeutics Inc stock on 29 November 2019 worth over 312,000$. On average, Kimberly trades about 4,154 units every 87 days since 2014. As of 28 August 2024 she still owns at least 10,000 units of Heron Therapeutics Inc stock.
You can see the complete history of Ms. Manhard stock trades at the bottom of the page.
Kimberly J. Manhard serves as Executive Vice President - Drug Development, Director of the Company. Ms. Manhard has more than 25 years of experience in drug development, regulatory affairs and pharmaceutical operations. From 2008 to 2016, she served as the Senior Vice President of Regulatory Affairs and Development Operations at Ardea Biosciences, Inc. In her role at Ardea, Ms. Manhard was instrumental in the development and 2015 regulatory approval of Zurampic® (lesinurad). Prior to joining Ardea in 2006, she was President of her own consultancy firm, Vice President of Regulatory Affairs for Exelixis, Inc. and held multiple regulatory positions at Agouron Pharmaceuticals, Inc., a division of the Warner-Lambert Company, supporting development and commercialization of anticancer and antiviral products, including Viracept® (nelfinavir). Ms. Manhard was also previously with Bristol-Myers Squibb Company in regulatory affairs, responsible for oncology compounds, including Taxol® (paclitaxel) and infectious disease compounds, including Videx® (didanosine) and Zerit® (stavudine). She began her career in clinical research with Eli Lilly and Company and G.H. Besselaar Associates (Covance Inc.). Ms. Manhard is a member of the board of trustees for the Fleet Science Center. She received a B.S. degree in zoology and a B.A. degree in French from the University of Florida.
As the Executive Vice President - Drug Development、 Director of Heron Therapeutics Inc, the total compensation of Kimberly Manhard at Heron Therapeutics Inc is 2,509,870$. There are 2 executives at Heron Therapeutics Inc getting paid more, with Barry Quart having the highest compensation of 5,870,480$.
Kimberly Manhard is 60, she's been the Executive Vice President - Drug Development、 Director of Heron Therapeutics Inc since 2019. There are 6 older and 14 younger executives at Heron Therapeutics Inc. The oldest executive at Heron Therapeutics Inc is Dr. Barry D. Quart, 64, who is the Chairman & CEO.
Kimberly's mailing address filed with the SEC is C/O INHIBRX BIOSCIENCES, INC., 11025 NORTH TORREY PINES ROAD, SUITE 140, LA JOLLA, CA, 92037.
Over the last 11 years, insiders at Heron Therapeutics Inc have traded over 96,663,574$ worth of Heron Therapeutics Inc stock and bought 6,549,746 units worth 56,275,132$ . The most active insiders traders include Kevin Ctang Capital Managem...、Adam Morgan、Craig A Collard. On average, Heron Therapeutics Inc executives and independent directors trade stock every 30 days with the average trade being worth of 176,989$. The most recent stock trade was executed by Craig A Collard on 19 July 2024, trading 13,797 units of HRTX stock currently worth 24,973$.
heron therapeutics, inc. (formerly a.p. pharma, inc.) is a specialty pharmaceutical company developing products using its proprietary biochronomer™ polymer-based drug delivery platform. this drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by converting them from products that must be injected once or twice per day to products that need to be injected only once every one or two weeks.
Heron Therapeutics Inc executives and other stock owners filed with the SEC include: